EP
PTCT icon

Edgestream Partners’s PTC Therapeutics PTCT Stock Holding History

Edgestream Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,314
Closed -$566K – 1098
2026
Q1 		$566K Buy
+8,314
New +$589K 0.02% 724
2025
Q2 		– Sell
-8,196
Closed -$418K – 1026
2025
Q1 		$418K Buy
+8,196
New +$409K 0.01% 722
2024
Q4 		– Sell
-30,383
Closed -$1.13M – 1038
2024
Q3 		$1.13M Buy
30,383
+8,303
+38% +$278K 0.05% 544
2024
Q2 		$675K Sell
22,080
-31,442
-59% -$1.02M 0.03% 616
2024
Q1 		$1.56M Buy
53,522
+17,681
+49% +$495K 0.08% 400
2023
Q4 		$988K Buy
+35,841
New +$820K 0.07% 445

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Edgestream Partners's PTCT Position: Q2 2026 in Review

Edgestream Partners sold out of PTC Therapeutics (PTCT) in Q2 2026, closing a stake of 8,314 shares — an estimated $566K sold.

Edgestream Partners first reported a position in PTCT in Q4 2023 and held it in 6 quarters. The position peaked at $1.56M in Q1 2024. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Edgestream Partners reported no remaining PTC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Edgestream Partners sold 8,314 PTC Therapeutics shares in Q2 2026, an estimated $566K.
  • Edgestream Partners first reported a position in PTC Therapeutics in Q4 2023 and held it in 6 quarters.
  • Edgestream Partners's PTC Therapeutics position peaked at $1.56M in Q1 2024.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.